SIGLEC1 as a Prognostic Factor in Colorectal Cancer
Author Information
Author(s): Zhu Yejin, Wang Xinping, Wang Qianyi, Shi Shanfan, He Jun, Jiang Chao
Primary Institution: Nanjing University of Chinese Medicine
Hypothesis
The study investigates the prognostic significance of SIGLEC1 in colorectal cancer and its regulation by Yiqi Huayu Jiedu Decoction.
Conclusion
SIGLEC1 is identified as an independent prognostic factor for colorectal cancer, linked to immune response and modulated by YHJD treatment.
Supporting Evidence
- SIGLEC1 expression was lower in tumor samples compared to control samples.
- Patients with higher SIGLEC1 expression had poorer survival outcomes.
- YHJD treatment increased SIGLEC1 expression in clinical samples.
- Univariate and multivariate analyses confirmed SIGLEC1 as an independent prognostic factor.
Takeaway
This study found that a protein called SIGLEC1 can help predict how well people with colorectal cancer will do, and a traditional medicine can change its levels.
Methodology
The study used bioinformatics analyses and clinical sample evaluations to assess SIGLEC1 expression and its correlation with survival outcomes in colorectal cancer patients.
Potential Biases
Potential biases may arise from sample selection and the inherent variability in tumor microenvironments.
Limitations
The study may be limited by tumor heterogeneity and variations in patient demographics.
Participant Demographics
The study included 16 patients with locally resectable colorectal cancer, with data on gender and age collected.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website